2657-85-4 Usage
Uses
Used in Pharmaceutical Industry:
4-Amino-N-(3-Aminophenyl)-Benzamide is used as a building block for the synthesis of pharmaceutical compounds, leveraging its reactive functional groups to form new molecules with potential therapeutic effects.
Used in Chemical Industry:
In the chemical industry, 4-Amino-N-(3-Aminophenyl)-Benzamide serves as an intermediate in the production of various organic compounds, contributing to the development of novel materials and chemical products.
Used in Research and Development:
4-Amino-N-(3-Aminophenyl)-Benzamide is utilized as a subject of study in research and development labs, where its properties and reactivity are explored to advance the understanding of organic synthesis and medicinal chemistry.
Used in Drug Design and Development:
As a promising candidate for drug design, 4-Amino-N-(3-Aminophenyl)-Benzamide is employed in the development of new pharmaceutical agents, potentially leading to the creation of innovative treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 2657-85-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,6,5 and 7 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2657-85:
(6*2)+(5*6)+(4*5)+(3*7)+(2*8)+(1*5)=104
104 % 10 = 4
So 2657-85-4 is a valid CAS Registry Number.
2657-85-4Relevant academic research and scientific papers
Synthesis and structure-activity relationships of small-molecular di-basic esters, amides and carbamates as flaviviral protease inhibitors
Sundermann, Tom R.,Benzin, Clarissa V.,Dra?i?, Tonko,Klein, Christian D.
, p. 187 - 194 (2019/05/21)
Inhibitors of the flaviviral serine proteases, which are crucial for the replication of dengue and West-Nile virus, have attracted much attention over the last years. A dibasic 4-guanidinobenzoate was previously reported as inhibitor of the dengue protease with potency in the low-micromolar range. In the present study, this lead structure was modified with the intent to explore structure-activity relationships and obtain compounds with increased drug-likeness. Substitutions of the guanidine moieties, the aromatic rings, and the ester with other functionalities were evaluated. All changes were accompanied by a loss of inhibition, indicating that the 4-guanidinobenzoate scaffold is an essential element of this compound class. Further experiments indicate that the target recognition of the compounds involves the reversible formation of a covalent adduct.
